Soluble Fas: a novel predictor of XXXX in dialysis @entity1 .

@entity1 @entity32 @entity1007 @entity6 @entity101 @entity12 @entity731 @entity204 @entity65 @entity454
BACKGROUND: @entity65 ( @entity65 ) is the leading cause of @entity204 in @entity1 with @entity454 ( @entity454 ). Disregulation of apoptosis within the vessel wall and upregulation of the @entity12 ( @entity12 ) system contribute to the development of @entity731 . Cross-sectional studies have suggested that elevated plasma levels of the soluble form of Fas (sFas) are associated with @entity65 . However, the role of sFas and sFas-L in predicting future cardiovascular events has yet to be defined. METHODS: We evaluated the role of plasma sFas and sFas-L levels as predictors of @entity65 in a prospective cohort of 107 chronic hemodialysis @entity1 . RESULTS: During the study period (27 months), 53 @entity1 (49.5%) presented with at least one cardiovascular end point. On univariate analysis, baseline sFas levels were significantly associated with the occurrence of cardiovascular end points, whereas sFas-L levels were not. Using Cox proportional hazards, increased sFas levels were associated with a significantly greater risk for cardiovascular end points (P = 0.03). This effect was independent of baseline @entity65 history, classic risk factors for @entity731 ( @entity6 , @entity1007 , @entity101 , and smoking), and markers of @entity32 (C-reactive protein [CRP], soluble intercellular adhesion molecule-1). Increased CRP levels also were associated with cardiovascular end points (P = 0.04). In addition, increased cardiovascular mortality was found in @entity1 in the highest sFas tertile compared with those in the lowest tertile (27.8% versus 8.6%; P = 0.04). CONCLUSION: Increased plasma sFas levels are predictive of future @entity65 . These results suggest that sFas is a novel and independent predictor of active @entity731 in @entity1 with @entity454 .
